Quantitative analysis for Context Therapeutics Inc. (CNTX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (3.0) (grade F). 27 signals analyzed (23 differentiated alt-data).
CNTX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $2.54 | $2.32 | $2.51 |
| 2026-05-08 | $2.40 | $2.27 | $2.38 |
| 2026-05-20 | $2.25 | $2.15 | $2.23 |
| 2026-06-02 | $2.80 | $2.42 | $2.42 |
| 2026-06-12 | $1.51 | $1.39 | $1.39 |
| 2026-06-25 | $0.61 | $0.55 | $0.56 |
| 2026-07-08 | $0.69 | $0.60 | $0.60 |
| 2026-07-20 | $0.63 | $0.59 | $0.62 |
| 2026-07-30 | $0.63 | $0.60 | $0.61 |
| 2026-08-12 | $0.48 | $0.45 | $0.47 |
| 2026-08-24 | $0.50 | $0.46 | $0.47 |
| 2026-09-03 | $0.38 | $0.35 | $0.36 |
How Context Therapeutics Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| INFU | InfuSystem Holdings, Inc. | $205M | — |
| BDTX | Black Diamond Therapeutics, Inc. | $206M | — |
| TENX | Tenax Therapeutics, Inc. | $206M | — |
| NBP | NovaBridge Biosciences | $203M | — |
View all Health Care stocks by valuation and signals →
Context Therapeutics Inc. (CNTX) scores Strong Sell (3.0), and the composite conceals a 78-point disagreement between its dimensions. It is strongest on analyst consensus at 79, and weakest on technicals at 2 and competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 79 |
| technicals | 2 |
| competitive moat | 1 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Context Therapeutics Inc. (CNTX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CNTX"><img src="https://stoquant.com/badge/CNTX.svg" alt="Context Therapeutics Inc. (CNTX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.